The S&P/ASX 200 Index (ASX: XJO) is back in positive territory on Thursday after a tough start to September.

At the time of writing, the benchmark index is up 0.46% to 9,019 points, recovering part of Wednesday’s 0.97% fall.

The move is also fairly broad, with 116 ASX 200 shares trading higher, compared with 73 fallers and 11 unchanged.

If the gains hold through the afternoon, it would also end a 3-day losing run for the stock market.

So, what is helping the ASX 200 rebound today?

US markets back in the green

Investors had a much better lead to work with this morning after Wall Street snapped a 3-day losing streak overnight.

The Dow Jones Industrial Average Index (DJX: .DJI) rose 0.56%, while the S&P 500 Index (SP: .INX) gained 0.46%, and the Nasdaq Composite Index (NASDAQ: .IXIC) added 0.45%.

Bond yields also settled down a little after jumping earlier in the session. The US 10-year Treasury yield briefly moved above 4.8% before easing back.

Oil prices remain another thing investors are watching, with Brent crude around US$95.63 as tensions between the US and Iran continue to support prices.

Big gains in key sectors are helping

Most of the support is coming from two of the biggest sectors in the market.

ANZ Group Holdings Ltd (ASX: ANZ) shares are up 1.76% to $38.17, while Westpac Banking Corp (ASX: WBC) is 1.59% higher at $34.94.

National Australia Bank Ltd (ASX: NAB) shares have gained 1.58% to $39.19, and Commonwealth Bank of Australia (ASX: CBA) is up 0.76% to $160.53.

And there’s plenty of strength among the miners.

Rio Tinto Ltd (ASX: RIO) shares are up 1.63% to $177.73, while Fortescue Ltd (ASX: FMG) has climbed 2.59% to $17.04.

Gold miners are also performing well, with Northern Star Resources Ltd (ASX: NST) up 2.46% to $23.14 and Evolution Mining Ltd (ASX: EVN) gaining 2.09% to $14.94.

The ASX 200 could be even higher

The ASX 200 is higher despite several large stocks trading lower as they go ex-dividend today.

BHP Group Ltd (ASX: BHP) shares are down 0.85% to $64.10, Woodside Energy Group Ltd (ASX: WDS) has fallen 2.78% to $32.16, while Coles Group Ltd (ASX: COL) is 1.82% lower at $23.46.

According to IG, those dividends are taking around 31 points off the ASX 200 today.

This means the ASX 200 would be up even more today without those ex-dividend falls.

Nonetheless, investors are still watching oil prices and the growing chance of another RBA rate hike.

Market pricing is now putting the chance of a September increase at around 72%.

The post What’s behind the ASX 200 rebound today? appeared first on The Motley Fool Australia.

More reading

• Own BHP, Woodside or Coles shares? Here’s what investors should know
• The average superannuation balance for 45-year-olds in Australia in FY26. How does yours compare?
• How much is needed in superannuation for $1,000 in weekly passive income?
• Why is the ASX 200 having its worst day in 3 months?
• Why these ASX shares are worth watching closely today

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) mining shares are outperforming today, up 0.8%, while the broader index is up 0.5%.

Here are some new ratings and 12-month share price targets on 3 ASX 200 mining shares.

Catalyst Metals Ltd (ASX: CYL)

The Catalyst Metals share price is $6.89, up 3.5% today and down 15% over 12 months. 

Morgans has a buy rating on this ASX 200 gold share following its June quarter report. 

The broker said: 

CYL reported record production at Plutonic in Q4 to close out FY26, but we expect a softer FY27 outlook when guidance is released in late Sep-26.

Permitting timelines, the ramp-up of multiple new mines and a better understanding of processing capability are likely to drive a rebase of the Sep-25 10-year plan, potentially delaying the pathway to ~200kozpa.

As a result, we have amended our production forecasts and cost assumptions.

Following an analyst change, we retain our BUY recommendation with a revised price target of A$11.33 per share.

Sandfire Resources Ltd (ASX: SFR)

The Sandfire Resources share price is $22.49, up 0.5% today and up 84% over 12 months. 

Morgans downgraded the ASX 200 copper share from accumulate to hold after its FY26 results.

The broker said: 

SFR resumed dividends with a 35cps final dividend (+86% vs expectations) and we see scope for this to build further as its cash balance continues to grow with no drawn debt, supported by a favourable base metals price environment.

SFR’s asset quality, management quality and balance sheet strength, alongside emerging growth optionality, underpin its case as a core copper exposure for long-term investors, though the stock appears fully valued at current prices.

Move to HOLD (previously ACCUMULATE) with a $23ps target price.

PLS Group Ltd (ASX: PLS)

The PLS Group share price is $5.31, up 2.3% today and up 132% over 12 months.

Morgans has a sell call on this ASX 200 lithium share.

Analyst Annabelle Sleeman explained:

Depleted lithium inventories leave scope for short-term upside, though we see the medium-term outlook as more volatile given uncertainty around supply and demand drivers.

PLS delivered an in-line FY26 Underlying EBITDA result and surprised with a maiden 5cps fully franked final dividend (22% FCF payout).

We view PLS as fairly valued at current levels, with its premium to peers already reflecting the company’s best-in-class execution, balance sheet and growth optionality.

The post Buy, hold, sell: PLS Group, Catalyst Metals, Sandfire Resources shares appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: NAB, PLS Group, Wesfarmers shares
• Why is the ASX 200 having its worst day in 3 months?
• Why these ASX shares are worth watching closely today
• 5 things to watch on the ASX 200 on Wednesday
• This exciting ASX 300 stock has 89% upside: Broker

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Orthocell Ltd (ASX: OCC) shares are down more than 35% over the past year, but the analysts at Bell Potter believe a recovery is on the cards.

They have a bullish share price target on the company, which I’ll get to shortly.

Biotech focused on bone and soft tissue repair

So what does the company actually do?

In their own words:

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell’s portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications.

Now let’s look at the company’s recent full-year results release.

Orthocell generated $13.2 million in revenue for FY26, up 45%, but its net loss also increased, jumping 59% to $13.6 million.

Chief Executive Officer Paul Anderson said:

FY26 was an important step in Orthocell’s evolution as a global regenerative medicine company, with record revenue and continued progress across established markets and selected international opportunities. We delivered record revenue of $13.2 million, up 45% on FY25, including a record June quarter of $3.8 million. Remplir and Striate were the principal drivers, supported by continued strength in Australia and growing contributions from the United States and other international markets.

Mr Anderson said Australia was the company’s most established market and was expected to continue growing, while FY26 was the first full year of Remplir’s availability in the US.

He said further re the US market:

We are very pleased with this first-year progress, while recognising that the path from surgeon interest to hospital approval, first use and repeat ordering can extend over several months. In FY27, our priority is to deepen adoption within the established footprint by investing in targeted sales, education and marketing initiatives that support distributors and surgeons as Remplir becomes part of routine clinical practice and repeat use grows.

Shares looking cheap according to broker

Bell Potter said in its note to clients that the US would be the market to watch.

They said:

US access expanded strongly in FY26, but revenue has yet to scale in line with the footprint. The key watchpoint now shifts to repeat utilisation and revenue conversion, which management has highlighted as a core FY27 priority. This is consistent with our prior view and leaves the broader thesis intact. We maintain our Buy (speculative) rating and reduce valuation to $1.13 from $1.19 following earnings adjustments.

Orthocell shares are currently changing hands for 72.5 cents. The company is valued at $196.1 million.

The post Bell Potter says this ASX biotech could rise 56% appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: South32, Australian Finance Group, Magellan shares
• This ASX lithium project developer could rise more than 300%: Broker
• Top 3 ASX 200 shares that lifted their dividend this reporting season
• Xero shares jump 33% from a 7-year low: Buy, sell or hold?
• Warning: Corporate Travel shares have crashed 80%. What on earth just happened?

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Orthocell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.